Echo Therapeutics Initiates Clinical Trials of its Symphony tCGM System in Critical Care Patients
Echo Therapeutics, Inc. (Nasdaq: ECTE) today announced that it is initiating clinical studies of its Symphony tCGM System in critical care patients. The company expects to complete and announce the results of the studies in the near term.
"We are very excited to initiate patient enrollment in our next studies of the Symphony system in the important hospital critical care setting," said Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics. "The goal of these trials is to demonstrate Symphony's performance in the large and emerging critical care market for non-invasive continuous glucose monitoring. We believe that Symphony addresses this unmet need, potentially improving patient outcomes."
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.